PDA

View Full Version : General Cancer News


Pages : 1 2 3 4 5 6 7 8 9 10 [11] 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51

  1. Cancer-related expenditures increase faster than any other area of health care: JAMA
  2. FXR can slow the growth of tamoxifen-resistant breast cancer cells: Study
  3. Wellstar International to install TMI Imaging system in Beverly Hills
  4. FDHN announces 2010 AGA Research Scholars
  5. After bad publicity, insurer to act early on ending practice of canceling policies of
  6. Neoprobe reports revenues of $2.7M for first-quarter 2010
  7. Imaging costs for Medicare cancer patients on the rise
  8. Three new biomarkers for ductal carcinoma in situ found
  9. WellPoint profits rise 51 percent amid scrutiny on several fronts
  10. HHS Secretary's statement on WellPoint's announcement to end practice of rescissions
  11. Power3 Medical Products to present four abstracts at International Congress of Alzhei
  12. AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010
  13. Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metast
  14. Women with family history of breast cancer face increase risk of ovarian cancer
  15. Immunogen reports a net loss of $12.1 million in third quarter 2010
  16. Study confirms MammaPrint's capabilities in determining patients likely to benefit fr
  17. Jumping elements in primates may have important consequences for studies of human gen
  18. HHS Secretary to host web chat to discuss impact of newly passed health insurance ref
  19. Update on BioSante cancer vaccine portfolio to be presented at BIO International Conv
  20. Leading experts deliver breast cancer updates at unique public forum
  21. McGill scientist discovers how one particular gene regulates epithelial cells
  22. Smoking can increase risk of second cancer in breast cancer survivors
  23. Obese women more likely to have breast cancer at later stage: Study
  24. ZIOPHARM reports a net loss of $17.7 million in first quarter 2010
  25. Research roundup: Managing nursing home patients, streamlining medical billing, finan
  26. New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor
  27. BSGI improves breast cancer detection
  28. PEAK Surgical announces positive results from two PRECISE Clinical Studies for breast
  29. BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development
  30. Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma
  31. FDA issues advisory on prostate cancer drugs
  32. NIH awards UIC $10M grant to study health disparities among underserved, minority wom
  33. NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in His
  34. Broccoli component sulforaphane targets and kills breast cancer stem cells
  35. Drive for expediency should not compromise care in breast cancer diagnosis, treatment
  36. Study comparing enteroscopy technologies finds SE quicker than DBE for examining smal
  37. Celsion reports $4.6 million net loss from operations for first-quarter 2010
  38. GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11
  39. Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study
  40. Celldex reports net loss of $6.6 million for first-quarter 2010
  41. Popular diabetes drug works differently than thought
  42. Scientists discover key molecular mechanism in breast cancer metastasis
  43. FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis pat
  44. Principals of StemTroniX, Power3 Medical Products file patent application
  45. Survey reveals need for educating U.S. women about stroke symptoms
  46. Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010
  47. C. R. Bard reaches definitive agreement to acquire SenoRx
  48. Whole body MRI helps physicians diagnose and treat breast cancer: Study
  49. Watson Laboratories files raloxifene hydrochloride tablet ANDA
  50. Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter
  51. Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010
  52. CU-Boulder develops inhalable vaccine for measles prevention
  53. Research reveals role of ovarian hormone progesterone in alteration of breast stem ce
  54. Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH re
  55. Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million
  56. A checklist to stay healthy at every age
  57. Natazia tablets receive FDA approval for prevention of pregnancy
  58. Progestins increase chances of cancer metastasizing, finds study
  59. Gene patenting policies affect patient access to testing for disease-causing genes: S
  60. New research examines coping and appraisal of disease-related pain
  61. NPWH launches ETIQ campaign to improve access to information about menopause, estroge
  62. Creator of California Tay-Sachs Disease Prevention Program among the honorees
  63. Discovery of new genetic clues to breast cancer
  64. Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin
  65. Double mastectomy best for long-term prognosis of breast cancer
  66. More genetic sites associated with increase in breast cancer risk discovered
  67. Enzon reports income from continuing operations of $20.8M for first-quarter 2010
  68. New combination therapy may help treat anti-estrogen resistant ER+ breast cancer
  69. Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%
  70. Minn. negotiators seek compromise to expand Medicaid while a nursing home tax and cut
  71. Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in p
  72. Exelixis first-quarter revenues increase to $42.2 million
  73. Bionovo reports net loss of $4.7M for first-quarter 2010
  74. Tensions escalate between Obama administration, health insurers
  75. New computer-based tool developed to benefit cancer patients
  76. Genetic tests represent future of cancer care for women
  77. Older women want more information about breast cancer, breast screening: Survey
  78. CTI to conduct phase II study of pixantrone in metastatic breast cancer through NCCTG
  79. Researchers develop new approach to immunotherapy of cancer
  80. 27-year-old sickle cell disease patient undergoes multiple joint replacement surgery
  81. CyGene Laboratories reports heightened interest in at-home genetic testing
  82. TechniScan awarded U.S. Patent covering design of 3-D, Warm Bath Ultrasound system
  83. Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010
  84. DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary
  85. New research to improve treatment for oesophageal and upper stomach cancer
  86. Measuring gene expression in healthy women may predict future breast cancer risk, say
  87. BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million
  88. Novartis employees and colleagues join together to raise money for community organiza
  89. Power3 Medical Products files provisional patent applications with USPTO
  90. EvoLife Laboratories participates in ONS Congress 2010 to assist nurses, caregivers
  91. United Spinal Association and ICS co-sponsor first annual conference to empower women
  92. Twenty rising juniors to create bras during summer break
  93. Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award
  94. Cancer 'epidemic' isn't happening
  95. Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal
  96. 152 research and training grants awarded to researchers at 93 institutions nationwide
  97. Woman with higher blood levels of IGF-I more likely to develop breast cancer: Study
  98. Abviva receives Japanese patent for Mammastatin Serum Assay
  99. Neoprobe gamma radiation detection systems featured in RSL peer review in American Jo
  100. Researchers discover biological pathway signature of ccRCC
  101. Generex Biotechnology's Phase I study data of AE37 for prostate cancer published
  102. University of Arkansas to host the 2010 Advances in Breast Cancer Research workshop
  103. ASCO first peek
  104. Wellpoint CEO Braly faces sharp criticism at shareholders meeting
  105. Research shows improved treatment of severe epilepsy reduces overall cost of the cond
  106. Mutation in BRCA1 tumor suppressor gene helps develop breast, ovarian cancer: Study
  107. 70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommenda
  108. British Columbians lead the way in battle against cancer
  109. Canadian Cancer Statistics 2010 focuses on care, support for dying patients
  110. Nine facilities in northern California region named Centers of Excellence in accelera
  111. Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin
  112. Loved ones can fill in gaping blanks about brain cancer patients' well-being: Study
  113. Genentech to present new data for targeted cancer medicines at 46th ASCO
  114. Data from three Phase II clinical trials of PS-targeting antibody to be presented at
  115. 'Teachable moments' can reduce cancer risk in children of parents with mutations in t
  116. New data highlighting Pfizer's approach to cancer drug development to be presented at
  117. Researchers discover key gene that promotes development of common kidney cancer
  118. Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian can
  119. Provectus to present further positive data from PV-10 Phase 2 clinical trial for meta
  120. ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma
  121. Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presen
  122. Data on serum DNA blood tests for early detection of cancer to be presented at ASCO 2
  123. New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010
  124. Women exposed prenatally to BPA or DES at increased risk of breast cancer: Study
  125. Abviva receives new patent grant notifications for MSA technology
  126. Scientists develop DNA-vaccine that restricts supply of blood to tumours
  127. Delphinus Medical Technologies secures $8M in venture capital to commercialize SoftVu
  128. Regulators puzzling out what insurers must do under new health law
  129. ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO
  130. Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells
  131. State Roundup: Oklahoma, S.C. and Ill. facing tough choices on health costs
  132. RCSI researchers identify biomarker that can predict severity of breast cancer
  133. Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept
  134. Highlights from June 2010 issue of American Journal of Pathology
  135. Breast-conserving therapy is viable treatment option for African-American women: Rese
  136. Study assesses possible links between pain medications and recurrent breast cancer ri
  137. Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: St
  138. Study finds improvement in detection of breast cancer in mammograms over 9-year perio
  139. Local businesswoman nominated for Outstanding Contribution to Breast Cancer Campaign
  140. Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, a
  141. Local school nominated for Breast Cancer Campaign's School of the Year award
  142. Active charity supporter nominated for Breast Cancer Campaign's Fundraiser of the Yea
  143. Amgen announces European approval of Prolia
  144. IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report
  145. First Edition: May 28, 2010
  146. Thyroid cancer gene marker
  147. Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes:
  148. LCRF to donate $25,000 for lung cancer studies at TGen
  149. Health law implementation deadlines missed, GOP offers repeal bill
  150. Exposure in womb to BPA, DES increase offspring's risk of breast cancer
  151. Crowne Plaza Invitational at Colonial hosts second annual Pink Out to raise awareness
  152. Women who undergo bilateral oophorectomy tend to have smaller tumors
  153. IMRT avoids xerostomia, but effectiveness on controlling cancer unclear
  154. Free educational forum tailored to the needs of people diagnosed with breast cancer
  155. Elekta acquires Resonant Medical
  156. GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis
  157. Cancer patients should find ways to be physically active during and after treatment:
  158. Prototype breast cancer vaccine shows promising results on mice
  159. TapImmune signs Licensing Option agreement with Mayo Clinic for breast cancer vaccine
  160. FDA grants priority review status to Eisai's eribulin NDA
  161. Oncimmune develops new blood test to aid early detection of cancer
  162. Targeted monoclonal antibodies show promise for pancreatic and metastatic breast canc
  163. Genes influence AIAA side effect in breast cancer survivors
  164. Chronix Biomedical to launch new disease detection, monitoring service for cancer res
  165. Discovery provides new therapeutic target to prevent loss of brain function
  166. PMRT increases breast cancer patients' five-year overall survival by almost 50%: Stud
  167. Olive oil produces greater weight loss in breast cancer survivors: Researchers
  168. Extracts from peach and plum kill breast cancer cells, say AgriLife Research scientis
  169. Nanosponge delivery system more effective at reducing tumor growth than direct inject
  170. Researchers identify new therapeutic target for cognitive decline
  171. Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study
  172. Discovery reveals a new approach to target cancer
  173. Study provides personalized strategies to boost AIAA compliance in breast cancer pati
  174. BSGI effective for evaluating unclear mammographic or ultrasound findings
  175. ELLICSR research centre opened at UHN
  176. Wolverine Venture Fund participates in $8M series A round of financing for Delphinus
  177. China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million
  178. Chemotherapy-induced amenorrhea improves survival in premenopausal women with early s
  179. Life Technologies partners to create Genomic Cancer Care Alliance
  180. Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemo
  181. Antiemetic-regimen with fosaprepitant injection provides similar protection against C
  182. Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASC
  183. Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC
  184. Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 20
  185. Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway target
  186. USC to present promising new findings in cancer research at 2010 ASCO
  187. New clinical research findings on oncology to be highlighted at ASCO 2010
  188. Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be pr
  189. Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented a
  190. Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced bre
  191. Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive m
  192. bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index cl
  193. AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recu
  194. Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metasta
  195. Bisphosphonates may cause poorer survival rate in women with early stage breast cance
  196. Arrhythmia Alliance launches 'Know Your Pulse' global awareness campaign on World Hea
  197. Clinical trial data of imetelstat in patients with breast cancer presented at ASCO an
  198. Chronix's serum DNA assays have potential to detect early stage breast cancer, prosta
  199. BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation
  200. Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Me
  201. Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at AS
  202. Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2
  203. Teen researches Artemesinin for cancer
  204. Lawsuit to be launched over breast cancer gene patent
  205. Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at
  206. ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma a
  207. Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at AS
  208. Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100%
  209. GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia
  210. Genta presents tesetaxel dose-ranging trial results at ASCO 2010
  211. Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer
  212. Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC pres
  213. Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-res
  214. Clarient granted U.K. patent for TLE3 biomarker
  215. New technique to prevent tumours developing in connection with stem cell transplantat
  216. Breast cancer research showcased at ASCO Annual Meeting
  217. Psychological intervention program teaches breast cancer patients how to cope with th
  218. Breast tomosynthesis holds promise for early breast cancer detection
  219. Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline
  220. Multiple presentations on nab-driven chemotherapy at 46th ASCO
  221. Stress-reducing psychological intervention helps increase quality of life among women
  222. University of Missouri researchers to investigate cadmium's potential for causing end
  223. Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metasta
  224. NICE decides not to recommend lapatinib for women with advanced breast cancer
  225. Scientists discover how polyphenols present in red wine and green tea inhibit prostat
  226. Baylor Institute of Immunology Research receives nearly $35M as grants in 2009
  227. 22 Midwest facilities named Centers of Excellence in accelerated partial breast irrad
  228. EC approves Nivestim for prevention of FN
  229. Are Dead Cancer Cells Feeding Cancer's Spread?
  230. iCAD to supply CAD technology for mammography to VA, Department of Defense Hospitals
  231. Ashikari Breast Center to participate in TARGiT intra-operative radiotherapy trial
  232. Older breast cancer women in Scotland do not receive same level of treatment as young
  233. UAB researchers win grant to study metastasis of dead cancer cells
  234. CTT's Calmare Pain Therapy Treatment shows promise against CIPN
  235. SBUMC uses RapidArc radiotherapy technology to treat cancer patients
  236. Budget cuts, poor fiscal management threaten breast cancer screening for needy women
  237. Interpretation of multiple gene function may hold clue to autism
  238. Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma
  239. AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting
  240. HL survivors do not receive recommended cancer screening tests: Study
  241. Study results of genes regulated by ERB published in Journal of Biological Chemistry
  242. Eribulin mesylate drug may help extend lives of women with advanced breast cancer
  243. DRIVE4COPD initiative aims to raise awareness of COPD
  244. How Carly Fiorina can cure her hot-mic 'hair' gaffe (cancer survivor)
  245. New guideline to improve IHC testing for expression status of ER and PgR in breast ca
  246. ARBs increase risk of cancer: Study
  247. Nurse with enhanced clinical skills detects same breast abnormalities as surgeon
  248. Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at AS
  249. Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC
  250. UCB announces availability of Vimpat oral solution formulation